Immunic Inc. reports third quarter net loss of $25.6 million

Reuters

2025/11/13

Immunic Inc. reports third quarter net loss of $25.6 million

Immunic Inc. reported a net loss of approximately $25.6 million, or $0.13 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $24.4 million, or $0.24 per share, for the same period in 2024. Research and development expenses for the quarter were $20.0 million, down from $21.4 million in the prior year quarter, mainly due to decreased external development costs related to IMU-856 and the completion of the phase 2 CALLIPER trial, partially offset by increased personnel expenses. Interest income for the nine months ended September 30, 2025, was $0.8 million, down from $3.0 million for the same period in 2024, primarily due to a lower average cash balance. During the period, key data from the phase 2 CALLIPER trial were presented, highlighting vidofludimus calcium's potential in progressive multiple sclerosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2228874_en), on November 13, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583561661"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583561661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583561661?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583561661","market":"us","top_or_hot":-1,"title":"Immunic Inc. reports third quarter net loss of $25.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. reports third quarter net loss of $25.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc. reported a net loss of approximately $25.6 million, or $0.13 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $24.4 million, or $0.24 per share, for the same period in 2024. Research and development expenses for the quarter were $20.0 million, down from $21.4 million in the prior year quarter, mainly due to decreased external development costs related to IMU-856 and the completion of the phase 2 CALLIPER trial, partially offset by increased personnel expenses. Interest income for the nine months ended September 30, 2025, was $0.8 million, down from $3.0 million for the same period in 2024, primarily due to a lower average cash balance. During the period, key data from the phase 2 CALLIPER trial were presented, highlighting vidofludimus calcium's potential in progressive multiple sclerosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2228874_en), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Inc. reports third quarter net loss of $25.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Inc. reports third quarter net loss of $25.6 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. reports third quarter net loss of $25.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc. reported a net loss of approximately $25.6 million, or $0.13 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $24.4 million, or $0.24 per share, for the same period in 2024. Research and development expenses for the quarter were $20.0 million, down from $21.4 million in the prior year quarter, mainly due to decreased external development costs related to IMU-856 and the completion of the phase 2 CALLIPER trial, partially offset by increased personnel expenses. Interest income for the nine months ended September 30, 2025, was $0.8 million, down from $3.0 million for the same period in 2024, primarily due to a lower average cash balance. During the period, key data from the phase 2 CALLIPER trial were presented, highlighting vidofludimus calcium's potential in progressive multiple sclerosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2228874_en), on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2t3hDR:1","article_id":"2583561661","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583561661","pubTimestamp":1763033511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunic Inc. reported a net loss of approximately $25.6 million, or $0.13 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $24.4 million, or $0.24 per share, for the same period in 2024. Research and development expenses for the quarter were $20.0 million, down from $21.4 million in the prior year quarter, mainly due to decreased external development costs related to IMU-856 and the completion of the phase 2 CALLIPER trial, partially offset by increased personnel expenses. Interest income for the nine months ended September 30, 2025, was $0.8 million, down from $3.0 million for the same period in 2024, primarily due to a lower average cash balance. During the period, key data from the phase 2 CALLIPER trial were presented, highlighting vidofludimus calcium's potential in progressive multiple sclerosis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMUX":"Immunic, Inc."},"translate_title":"Immunic Inc.报告第三季度净亏损2560万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Immunic Inc. reports third quarter net loss of $25.6 million\n    \n\n        Immunic Inc. reported a net loss of approximately $25.6 million, or $0.13 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $24.4 million, or $0.24 per share, for the same period in 2024. Research and development expenses for the quarter were $20.0 million, down from $21.4 million in the prior year quarter, mainly due to decreased external development costs related to IMU-856 and the completion of the phase 2 CALLIPER trial, partially offset by increased personnel expenses. Interest income for the nine months ended September 30, 2025, was $0.8 million, down from $3.0 million for the same period in 2024, primarily due to a lower average cash balance. During the period, key data from the phase 2 CALLIPER trial were presented, highlighting vidofludimus calcium's potential in progressive multiple sclerosis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2228874_en), on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}